MicroRNAs in Human Cancers with Researcher George Calin

38:42
 
Share
 

Manage episode 292229471 series 2469176
By Richard Jacobs. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Ninety-eight percent of the human genome is non-coding. The majority of our DNA instructs and regulates the other two percent. Until recently, this ninety-eight percent was considered junk DNA and held a mystery of purpose akin to dark matter. George Calin opens the mystery for listeners and explains how researching non-coding RNAs will lead to better cancer treatments. Listen and learn

  • How non-coding RNAs stay in the nucleus and other mechanistics,
  • Why early earth was an “RNA world,” and what that indicates about the evolution of life,
  • How non-coding RNAs are considered “double phase” and why that’s significant for therapeutics and mRNA vaccines, and
  • How his research on non-coding RNA biomarkers in body fluids should lead to targeted interventions.

George Calin is a principal investigator with the MD Anderson Cancer Center at the University of Texas. He specializes in how non-coding RNAs impact disease and virus mechanisms, specifically the role of microRNAs in human cancers. He also looks at what they can tell us about how bad and aggressive a particular disease will be for a specific individual. He notes that “a specific type of cancer with a specific localization at a specific stage. . . can behave very differently in another patient” with the same profile. “One is surviving, let's say one month, and other is surviving three years,” he adds, and researchers want to know why.

He says that mRNAs may have the answers and could point doctors in the direction of how to help both patients. It could lead to more aggressive measures when the biomarkers point toward that necessity, for example. Because cancer is a genetic disease, understanding the complexities of genes and genomics is vital to its treatment. By studying how and why and when abnormalities are expressed and what these non-coding RNAs are instructing, researchers can open up an entirely new way to treat cancers. He says that some of this biomarker identification is already in use for some bladder cancers. Listen in for more on how advancement in studying the smallest parts of us may make the biggest difference. Episode also available on Apple Podcasts: apple.co/30PvU9C

2879 episodes